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BIOMARKERS IN GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC 
HEMATOPOIETIC STEM CELL TRANSPLANT 
JOSHUA J. GEARY 
ABSTRACT 
 Hematopoietic stem cell transplant was developed as a curative therapy to treat 
onco-hematological diseases (Schütt et al. 2007), and recently indications for this therapy 
have expanded to include solid tumors, hemoglobinopathies and other genetic diseases 
and disorders (Steward and Jarisch 2005).  Two major types of hematopoietic stem cell 
transplant have been developed.  Autologous transplants aim to deliver a massive dose of 
radiation and/or chemotherapy that is capable of ablating the hematopoietic stem cells in 
the bone marrow. The patient is then “rescued” from this lethal dose of treatment by an 
infusion of their own hematopoietic stem cells.  Allogeneic transplants are designed to 
either functionally replace a cell class, or an enzyme or biological function absent in the 
patient, or to consolidate a remission in a onco-hematological disease via the graft-
versus-tumor effect (Ofran and Ritz 2008).  Two of the largest causes of non-relapse 
mortality from an allogeneic hematopoietic stem cell transplant are acute and chronic 
graft-versus-host disease, in which immune cells derived from the graft recognize normal 
host tissue as foreign and attack these tissues.  A host of biomarkers for acute graft versus 
host disease have been identified, but there is almost none for chronic graft versus host 
disease.  Herein, a methodology to discover and validate a biomarker(s) for the most 
common organ system affected by chronic graft versus host disease is proposed. 
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INTRODUCTION 
 
The first bone marrow transplants were born out of the US atomic energy program, as 
researchers strove to understand the mechanisms of radiation poisoning.  Animal studies 
showed that radiation poisoning led to a failure of hematopoiesis and that cells from the 
spleen and bone marrow were capable of restoring hematopoiesis.  E. Donnall Thomas 
performed and reported the first cases of syngeneic bone marrow transplants (Thomas et 
al. 1959). 
Over the course of the intervening years hematopoietic cell transplantation has grown 
as a field, and the techniques, cell sources, conditioning, and indications for 
hematopoietic stem cell transplantation have grown from onco-hematological diseases 
such as Hodgkin's and non-Hodgkin's lymphomas (Schütt et al. 2007), and multiple 
myeloma (Fermand et al. 1998), to include many other diseases.  Hematopoietic stem cell 
transplantation is now a standard of care for inherited metabolic storage disorders , severe 
autoimmune diseases, other genetic diseases (Steward and Jarisch 2005), as well as for 
some solid tumors, especially in the pediatric setting (Bochennek et al. 2012).   
Two major types of hematopoietic stem cell transplants have been developed over the 
years.  Traditionally, in both types of transplants, autologous (patients receive thawed 
autologous marrow or hematopoietic progenitor cells, apheresis), and allogeneic (patients 
generally receive fresh allogeneic stem cell-containing product) patients receive a 
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myeloablative conditioning regimen involving high dose total body irradiation and/or 
high dose chemotherapy agents (Bayraktar et al. 2013).  In both cases, the doses of 
chemotherapy and/or radiation are considered lethal doses, as they destroy hematopoiesis 
in the patient.   
Autologous transplants are indicated when clinicians wish to give a lethal dose of 
chemotherapy to ablate the bone marrow, and generally either clear the marrow of 
residual onco-hematological disease or to clear residual solid tumor (Fermand et al. 
1998).  Allogeneic stem cell transplant, the second major type of hematopoietic stem cell 
transplant, was developed as clinicians sought to leverage the graft-versus-tumor effect to 
treat onco-hematological and other diseases.  In this type of transplant, a donor is 
matched for several major human leukocyte antigens.  In a modern transplant setting, at 
least 4 antigens are tested at a genetic level; there are three type 1 antigens, A, B, C, 
which present peptides from inside the cell to cytotoxic T lymphocytes, and one type 2 
antigen, DR, which presents antigens from outside the cell to T-helper cells.  Matching 
these genes at an allelic level decreases the risk of graft failure and decreases the risk of 
graft-versus-host disease (GVHD) (Morishima et al. 2002).  The above-mentioned graft-
versus-tumor effect is mediated by the interactions between donor cytotoxic T 
lymphocytes, donor natural killer cells and recipient specific cell surface allo-antigens 
and tumor specific antigens (Ofran and Ritz 2008). 
Allogeneic hematopoietic stem cell transplants have been used to primarily treat 
onco-hematological diseases that respond poorly to treatment with chemotherapy agents.  
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Diseases such as acute myeloid leukemia (Clift et al. 1990), acute lymphoblastic 
leukemia (Terwey et al. 2013), chronic lymphocytic leukemia (Krejci et al. 2013), and 
chronic myeloid leukemia (Champlin et al. 2011) have been treated using allogeneic 
hematopoietic stem cell transplants with some success, increasing survival metrics for 
patients with these hard to treat diseases. 
More recently, several transplant centers have pioneered new, non-myeloablative 
conditioning regimens allowing more patients (especially those over the age of 65) to 
undergo allogeneic hematopoietic stem cell transplants (Shimoni and Nagler 2002).  
These reduced intensity transplants for onco-hematological diseases strictly rely on the 
adaptive immunotherapy provided by the graft-versus-tumor effect (Ofran and Ritz 
2008).  The conditioning regimens for these transplants do not deliver an otherwise lethal 
dose of chemotherapy or radiation to the patient.  Instead, they seek to clear some space 
in the bone marrow niche for the allogeneic hematopoietic stem cells to engraft, and 
avoid graft rejection by residual patient T cells (Servais, Baron, and Beguin 2011).  These 
reduced intensity transplants are also seeing use in pediatric and adult settings to correct 
single gene mutations, such as sickle cell disease, thalassemia, and severe combined 
immunodeficiency (Steward and Jarisch 2005).   
In addition to the growth of indications treatable with either autologous or allogeneic 
hematopoietic stem cell transplants, the number of cell sources has grown, each with 
advantages and disadvantages.  The first cell source used in transplants were preparations 
of freshly harvested marrow from syngeneic twins (Thomas et al. 1959).  Since then, 
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researchers have developed autologous transplants, which required the development of 
techniques from the field of cryobiology, allowing marrow to be cryopreserved and 
thawed safely, maintaining the integrity and function of cells (Berz et al. 2007).  In 
addition to marrow, hematopoietic cells are now routinely harvested via their 
mobilization from the marrow to the blood with various agents (Mohty and Ho 2011) and 
leukapheresis (Körbling and Freireich 2011).  These cells can be collected from the 
patient (autologous transplant) or from a donor (allogeneic).  As previously mentioned, 
researchers have worked to determine the most important human leukocyte antigen 
alleles, not only allowing transplants from related donors, but also unrelated donors with 
the same HLA alleles as the recipient.  To help identify potential unrelated donors, the 
National Marrow Donor Program was founded in 1986, in addition to other international 
registries also founded around this time.  Finally, cord blood banking began in the late 
1990’s and has made transplants available for patients who are not well-represented in 
international transplant registries, but still require allogeneic hematopoietic stem cell 
transplants (Murphy et al. 2010).  
Despite the growth of the field of hematopoietic stem cell transplantation, it is worth 
noting that it is not a trivial procedure and there are major complications and risks to this 
treatment.  When treating onco-hematological diseases, there is always a risk of disease 
relapse.  In many cases the hematopoietic stem cell transplant procedure is used as 
consolidation therapy, in an attempt to eradicate the last remaining neoplasm after the 
patient has achieved his or her best possible response to induction chemotherapy agents 
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(McCarthy and Hahn 2013).  Relapse rates vary between diseases and within diseases by 
status and cytogenetics (Schütt et al. 2007).  Myeloablative conditioning regimens lead to 
prolonged hematopoietic aplasia and immunologic suppression, leaving the patient at risk 
of developing opportunistic infections, requiring the transfusion of formed elements 
(such as platelets and red blood cells), granulocytes and pooled immunoglobulins. (Sorror 
et al. 2005).  Depending on the cell source, cell dose and conditioning regimen, this 
period lasts, on average around 2-3 weeks.   
If that was not enough, graft-versus-host disease, a dark reflection of the graft-versus-
tumor effect, is a very substantial risk factor in allogeneic transplants.  Briefly, despite 
the advances in human leukocyte antigen matching, and the development of prophylaxis 
measures, cells from the hematopoietic stem cell graft can recognize allo-antigens on host 
cells and attack the “foreign” cells and tissues.  To complicate matters further, graft-
versus-host disease is associated with an increased graft-versus-tumor effect and 
decreased risk of relapse (Storb et al. 2013).  The causes and presentation of this disease 
are heterogeneous, which in the past, led to differences between treatment centers in the 
diagnosis and scoring of the severity of this disease.  Studies conducted on GVHD prior 
to the establishment of consensus criteria can be confusing to interpret due to the various 
definitions of graft-versus-host disease (Filipovich et al. 2005).  This confusion and lack 
of clarity in diagnostic standards lead to the development of the NIH consensus criteria 
(Filipovich et al. 2005).  Briefly, the NIH consensus criteria defined two broad categories 
of GVHD, as well as a scoring system to help stratify risk and guide treatment: 
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The acute GVHD category is defined in the absence of diagnostic or distinctive 
features of chronic GVHD and includes (1) classic acute GVHD occurring within 
100 days after transplantation and (2) persistent, recurrent, or late acute GVHD” 
(features of acute GVHD occurring beyond 100 days, often during withdrawal of 
immune suppression) (Filipovich et al. 2005).  
The broad category of chronic GVHD includes (1) classic chronic GVHD 
(without features or characteristics of acute GVHD) and (2) an overlap syndrome 
in which diagnostic or distinctive features of chronic GVHD and acute GVHD 
appear together. It is currently recommended that systemic therapy be considered 
for patients who meet criteria for chronic GVHD of moderate to severe global 
severity (Filipovich et al. 2005).  
Diagnosis of chronic GVHD is established by the presence of diagnostic and/or 
distinctive manifestations at any time post-transplant.  To qualify as having classic 
chronic GVHD, a patient must either manifest at least one diagnostic clinical sign of 
chronic GVHD, or  the patient must manifest at least one distinctive manifestation of 
chronic GVHD confirmed by biopsy or other relevant test (read biomarker) in the 
absence of acute GVHD (Filipovich et al. 2005).  A diagnosis of overlap syndrome 
occurs when features of acute and chronic GVHD appear together.  That is to say a 
patient either manifests at least one diagnostic clinical sign of chronic GVHD, or the 
patient must manifest at least one distinctive manifestation of chronic GVHD confirmed 
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by biopsy or other relevant test (read biomarker) at the same time as clinical features of 
acute GVHD present (Filipovich et al. 2005).  
 Diagnostic clinical signs and distinctive manifestations vary according to the 
organ affected.  Skin chronic GVHD has many diagnostic manifestations, including 
distinctive features, as well as a number of common, non-distinctive manifestations that 
may belie the presence of skin chronic GVHD.   
Diagnostic manifestations include poikiloderma (e.g., atrophic and pigmentary 
changes), lichen planus-like eruption (e.g., erythematous/violaceous flat-topped 
papules or plaques with or without surface reticulations or a silvery or shiny 
appearance on direct light), deep sclerotic features (e.g., smooth, waxy, indurated 
skin—“thickened or tight skin,” caused by deep and diffuse sclerosis over a wide 
area), morphea-like superficial sclerotic features (e.g., localized patchy areas of 
moveable smooth or shiny skin with a leathery-like consistency, often with 
dyspigmentation), or lichen sclerosus-like lesions (e.g., discrete to coalescent gray 
to white moveable papules or plaques, often with follicular plugs, with a shiny 
appearance and leathery consistency). Severe sclerotic features characterized by 
thickened, tight, and fragile skin are often associated with poor wound healing, 
inadequate lymphatic drainage, and skin ulcers from minor trauma (Filipovich et 
al. 2005).   
Other tissues and organ systems generally have less diagnostic, distinctive and non-
distinctive manifestations, including chronic GVHD of the lung, which has only one, 
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biopsy-proven diagnostic, bronchiolitis obliterans (Filipovich et al. 2005).  Bronchiolitis 
obliterans in the setting of hematopoietic stem cell transplant is inevitably fatal unless the 
patient undergoes a lung transplant (Soubani et al. 2014).   
As previously stated, it is difficult to diagnose chronic GVHD, because it is a 
diagnosis of exclusion.  That is to say even in the presence of several diagnostic clinical 
signs or distinctive manifestations, other diseases and conditions that could lead to a 
similar clinical presentation must be ruled out due to a lack of definitive tests and 
biomarkers that indicate the presence or absence of the disease.   
Acute GVHD has a higher rate of morbidity and mortality than chronic GVHD, 
and since the advent of better diagnostics and treatments for other peri-transplant 
complications, it has become the leading cause of non-relapse mortality during the first 
one hundred days post-transplant (Lee et al. 2013).  Differentiation between late onset 
acute GVHD, acute GVHD, overlap syndrome and chronic GVHD in the NIH consensus 
criteria has been proven to be meaningful in terms of non-relapse mortality (Vigorito et 
al. 2009).  
After diagnosis of chronic GVHD or overlap syndrome, the NIH consensus 
criteria and scoring system for individual organs and the global score may be used to 
assess the severity of the patient’s disease and intervene appropriately (Filipovich et al. 
2005).  The scoring system has been validated for chronic GVHD, showing that the risk 
stratification of chronic GVHD in the NIH consensus criteria are meaningful in guiding 
treatment and predicting outcomes (Moon et al. 2014).   
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The consensus scoring system for individual organs, shown in Figure 1, allows for 
baseline and cross-sectional use and provides clinicians an easy method to acquire 
clinically relevant data regarding the extent and severity of disease (Filipovich et al. 
2005).  Each organ site of chronic GVHD is scored on a four-point scale, from 0, no 
symptoms present,to 3, which indicates severe impairment of the target organ sites 
(Filipovich et al. 2005).  The number of organ sites and severity of each site involved 
determine the global score of chronic graft versus host severity.  Mild chronic GVHD 
involves 1 to 2 organs (excluding the lungs) with a maximum score of 1 in all affected 
organs; moderate chronic GVHD involves (1) at least 1 organ or site with clinically 
significant but no major disability (maximum score of 2 in any affected organ or site) or 
(2) 3 or more organs or sites with no clinically significant functional impairment 
(maximum score of 1 in all affected organs or sites). A lung score of 1 will also be 
considered moderate chronic GVHD. Severe chronic GVHD indicates major disability 
caused by chronic GVHD (score of 3 in any organ or site). A lung score of 2 or greater 
will also be considered severe chronic GVHD (Filipovich et al. 2005).  Moderate and 
severe chronic GVHD have been proven to be an indication for systemic corticosteroid 
treatment, and perhaps multiple agent treatment depending on the clinical situation 
(Moon et al. 2014).  
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Figure 1: Organ scoring of chronic graft versus host disease. Adapted from Filipovich 
et al. 2005. 
Chronic GVHD contributes significantly to late (>100 days post transplants) non-relapse 
mortality, as shown Table 1 and Figure 2 (Pidala et al. 2011; Socié et al. 1999). 
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Figure 2: Non-relapse mortality according chronic graft versus host disease severity. 
Cumulative incidence of non-relapse mortality (y-axis) plotted against time in months 
after 100 days post-transplant landmark.  Grades of chronic graft versus host disease are 
given according to NIH consensus standard.  Higher grades significantly associated with 
a greater risk of non-relapse mortality.  244 patients were included in this study.  Adapted 
from Pidala et al. 2011. 
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Table 1: Primary causes of death among patients who were disease-free two years 
after transplantation.The burden of chronic graft versus host disease on long term 
survivors after an allogeneic hematopoietic stem cell transplant.  In long-term survivors, 
30% of deaths are attributable to graft versus host disease.  Adapted from Socié et al. 
1999. 
 
 
 
Even using the NIH consensus criteria, diagnosis of the GVHD is complicated, 
and risky.  Many of the presentations and symptoms of GVHD are similar to other peri-
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transplant and post-transplant diagnoses.  In some cases initiation of front line treatment 
for any type of GVHD, e.g. systemic corticosteroids, can be lethal if misdiagnosed 
(Filipovich et al. 2005).  Currently all types of GVHD are diagnosed by the presence or 
absence of symptoms, and confirmed with a biopsy of the affected tissues and organ 
system (Coron et al. 2014).  The sensitivity and specificity of this gold standard is below 
that of many other tests indicating certain disease conditions and the development of 
superior tools for diagnosis and confirmation of GVHD are required.  
As previously stated, and illustrated in Figure 1, chronic GVHD manifests in 
several target organs and tissues, including the skin, mouth, liver, lung, eye, fascia, 
gastrointestinal tract and genitals (Jacobsohn et al. 2012).  More than one tissue or organ 
may be affected by chronic GVHD.  It may co-present as an overlap syndrome in which 
diagnostic features of acute and chronic GVHD appear together (Filipovich et al. 2005).  
Recently some biomarkers have been identified for acute GVHD and are being tested in 
clinical trials in many hematopoietic stem cell transplant centers.  Suppressor of 
Tumeregency 2 (ST2) was recently developed and has been validated to diagnose acute 
GVHD and can predict transplant related mortality (Ponce et al. 2014) However only one 
biomarker has been validated for chronic GVHD (Devic et al. 2014), so there is a great 
need for biomarkers to distinguish chronic GVHD from other complications (Paczesny et 
al. 2013). 
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PUBLISHED STUDIES 
Now that GVHD has been defined and the need  for biomarkers to identify  chronic 
GVHD has been described,   some candidate biomarkers for this disease will be 
enumerated.  Simply stated a biomarker is a biological molecule found in body fluids 
and/or tissues that signifies the presence or absence of a normal or abnormal process, 
condition or disease.  It may be used to determine how the body will respond to treatment 
and may be used to guide risk stratification and treatment (“Definition of Biomarker - 
NCI Dictionary of Cancer Terms” 2015).  A biomarker can be a specific protein or 
enzyme found in the blood, urine or tissue, a specific circulating cell type (identified by 
cluster of differentiation markers as assayed by flow cytometry), or a type of ribonucleic 
acid, e.g. micro RNA, which can also be found in body fluid.  Some also consider pre-
transplant risk factors, such as the presence or absence of certain alleles in the recipient 
and/or donor, biomarkers; however, while these factors are important and worthwhile, 
they do not meet the later part of the standard definition of a biomarker (“Definition of 
Biomarker - NCI Dictionary of Cancer Terms” 2015).   
Cellular markers are of great interest in studying this particular disease, because 
immune cells expressing cluster of differentiation markers are the effector cells which are 
responsible for causing many of the symptoms and damage found in GVHD.  Several 
studies have examined the relative quantity of regulatory T cells, regulatory B cells, 
natural killer, cytotoxic T lymphocytes, and T helper subsets at various time points after 
transplant.  Greinix et al., have recently identified several populations of cells that 
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independently predict future onset of chronic GVHD in a discovery set (Greinix et al. 
2014; Kuzmina et al. 2011).  Sarantopoulos et al. have shown that B-cell activating factor 
and immature, or arrested, B cell phenotypes are correlated with active chronic GVHD 
(Sarantopoulos et al. 2007).  Finally, other groups have isolated regulatory T cells and 
analyzed the transcriptomes of these cells seeking to identify biomarkers that could be 
used both in the diagnosis of acute and chronic GVHD and to potentially identify 
response-to-treatment (Ukena et al. 2012).  It is worth noting that none of the candidate 
biomarkers identified by this body of literature have been validated.   
Micro ribonucleic acids (miRNA) are small, non-coding sequences of RNA that 
silence messenger RNA and post-transcriptionally regulate expression of genes.  
miRNAs are present in blood, and patterns of miRNA expression are indicative of normal 
function or pathology, including autoimmune diseases, such as systematic lupus 
erythematosus (Atarod and Dickinson 2013; Xie et al. 2014).  The technology for 
analyzing miRNAs lags behind both proteomics and analysis of cellular markers using 
flow cytometry techniques, and has yet to yield many candidate biomarkers for either 
acute of chronic GVHD (Paczesny et al. 2013). 
There are many types of potential biomarkers that can be found in various tissues and 
fluids.  Molecular techniques allow scientists to assay the concentrations of different 
proteins found in body fluids.  The field is well developed and there are a variety of tools 
researchers can use to identify potential biomarkers.  Researchers can select and detect 
levels of various proteins in serum or blood samples using either enzyme-linked 
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immunoabsorbent assays or multiplexed immunoassays in search of a biomarker for their 
disease of interest.  However, there are problems with this approach, including selection 
bias, for example, selecting cytokines and soluble cytokine receptors, rather than markers 
of tissue specific damage (Berger et al. 2013)  
In addition to selection bias, there are potential pitfalls that may arise with the 
molecular techniques used, including cross reactivity (Keustermans et al. 2013). In this 
situation, cross reactivity may be defined as a substance within the sample that raises or 
lowers the determined concentration of the protein from the true concentration of the 
protein in the sample.  In addition to this factor, factors affecting sample quality, 
including the anticoagulant used (if blood), the time from collection to processing (urine, 
serum, plasma), the length of time in storage at -80
0
 C (serum and plasma), and the 
number of “freeze-thaws” specimens undergo can radically change the results obtained 
via these molecular methods (Parkitny et al. 2013; Keustermans et al. 2013).  Despite the 
pitfalls, there are significant advantages that can be leveraged using molecular techniques 
to identify and detect biomarkers.  Many hematopoietic transplant centers keep an 
archive of samples collected at various timepoints from patients undergoing transplant 
procedures.  Combining the readily accessible number of samples available and these 
techniques can lead to a study with great statistical power that can look at the levels of 
specific candidate biomarkers at various time points easily (Paczesny 2013). 
Proteomics, the study of all of the proteins expressed by a specific cell, tissue, organ 
or organism is a powerful tool to screen potential biomarkers.  Mass spectrometry and 
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high performance liquid chromatography have been used to detect, with absolute 
specificity, the identity and concentration of proteins in two samples representing two 
experimental conditions (Faca et al. 2006).  There are two general workflows that have 
been used in biomarker identification in transplantation and both usually leverage a 
similar method to quantify protein concentration, i.e., liquid chromatography tandem 
mass spectrometry (LC MS/MS) (Faca et al. 2006), but get to this step in different ways.  
These workflows are known as top-down and bottom-up, or shotgun proteomics.   
Bottom-up proteomics workflows are more established, but present some 
disadvantages when used to identify biomarkers (Parks et al. 2007).  Briefly, bottom-up 
proteomics work flows involve the digestion of complex protein mixtures using trypsin, 
yielding a peptide mixture that is generally labeled with isobaric tags (e.g., condition A is 
labeled with heavy isotopes of carbon and nitrogen and condition B is labeled with light 
isotopes) prior to separation and analysis (Han, Aslanian, and Yates 2008).  During 
analysis the relative concentration and identity of proteins in the sample is determined via 
an algorithm based on the peptides detected by the mass spectrometer (Han, Aslanian, 
and Yates 2008).   
Top-down proteomics eliminates the upfront digestion of proteins in a sample into a 
peptide mixture.  Instead it relies on labeling proteins in a sample with isobaric tags 
before upfront fractionation of the sample using liquid chromatography.  After the 
undigested proteins have been tagged, they are ionized in the gas phase.  The ionized, 
intact proteins are assayed by mass spectrometry, then are directly fragmented and inside 
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the mass spectrometer by electron-capture dissociation or electron-transfer dissociation 
and re-analyzed to determine the identity and concentration of proteins with absolute 
specificity (Han, Aslanian, and Yates 2008).   
Originally bottom-up approaches were favored in biomarker identification because of 
the wide dynamic range of analyses, and robustness of the methodology.  Key work by 
Park and Han led to an increase in the dynamic range and usability of top-down 
approaches (Han et al. 2006; Parks et al. 2007).  This, coupled with improvements in 
algorithms used to identify proteins given the MS/MS spectra, and the ability of top-
down proteomics work flow to identify proteins and quantify them absolutely in two 
different experimental conditions, to identify post-translation modifications, and to 
identify smaller proteins, under 30 kilodaltons (proteins this small may not have trypsin 
cleavage sites), that may be biologically relevant, makes top-down proteomics superior 
for biomarker discovery (Parks et al. 2007).  However, depending on sample source, 
institutional expertise and equipment, bottom-up approaches can be utilized as well 
(Devic et al. 2014). 
When using top-down or bottom-up proteomic analyses to identify potential 
biomarkers for a disease condition, the required power of the study, thus the number of 
samples required, is an order of magnitude lower than required when using 
immunoassays.  Between 10 and 20 unique samples collected from control patients and 
patients exhibiting the disease condition are required for analysis (Paczesny 2013).  The 
sample can be serum, plasma or other body fluids (Devic et al. 2014). As discussed, the 
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selection, preparation and storage are critical to ensuring that the experimental results, i.e. 
presence/absence, concentration, reflect the presence or absence of the disease state as 
opposed to effects introduced by poor handling (Keustermans et al. 2013).  Once the 
mass spectra are analyzed, there are generally between 10-200 proteins that differ in 
concentration greater than two-fold between the two conditions (Ferrara et al. 2011).   
Researchers choose targets for validation based on biological activity, availability of 
commercially available antibodies, and preferential expression in the target organ(s), if 
applicable (Hanash, Pitteri, and Faca 2008).  The validation set (hundreds of patients and 
samples), is then analyzed with ELISA or multiplex studies (Ferrara et al. 2011).  The 
validation set should include patients from multiple transplant centers, with samples 
stored under standard and consistent conditions.  After validation of the biomarker, 
additional prospective studies must be developed to determine the utility of this 
biomarker in guiding clinical decisions and interventions.   
Each technique discussed above, miRNA, flow cytometry, and proteomic analysis has 
advantages and disadvantages.  The most logical and established method of biomarker 
discovery involves LC-MS/MS screening using top-down or bottom-up methodology 
followed by validation using standard immunological methods (Paczesny 2013).  Not 
only is this methodology robust, with a history of delivering results, but it has a lower 
cost and technical barrier to entry than some of the newer techniques used to identify 
biomarkers.  However, the costs of performing these studies are not trivial. 
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Assuming adequate resources are available, there remain recurring and additional 
concerns. The acquisition, processing and storage of samples are critical and must be 
appropriately managed for both the mass spectrometry analysis to yield potential targets 
for validation and for follow-up validation studies and clinical trials.  Multiple studies 
have shown that the preparation of samples prior to processing and storage conditions can 
affect the measured concentration of cytokines and other volatiles (Chaturvedi et al. 
2011; Parkitny et al. 2013; Keustermans et al. 2013) as measured by either single or 
multiplexed immunoplex assays.  In addition to concerns regarding the samples used in a 
study there are additional concerns that must be considered when designing all phases of 
a biomarker discovery study.  
As discussed in the introduction there are a host of underlying diseases that can be 
treated with allogeneic hematopoietic stem cell transplant, and a variety of conditioning 
regimens and GVHD prophylaxis strategies used among transplant centers.  There are 
also at least three cell sources for allogeneic transplants, including HPC, Apheresis, HPC, 
Marrow and HPC, Cord Blood.  These source materials can be manipulated in vivo or ex 
vivo to functionally alter a population, i.e. enrich or reduce specific populations of cells 
(Marek et al. 2014).  In addition to all the confounding factors listed above, transplant 
patients tend to be of somewhat advanced age, especially in the adult setting; therefore it 
may be worthwhile to eliminate this confounding variable by running validation studies 
of the candidate biomarker with age-matched, disease-free patient controls (Devic et al. 
2014). 
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After identifying a candidate biomarker, and dealing with the above-mentioned 
confounding variables and concerns relevant to experimental design, the validation set 
provides the first chance to determine the potential clinical usefulness of the candidate 
biomarker.  Ideally, a biomarker should have predictive properties, with some sensitivity 
and specificity, regarding whether or not the disease in question will manifest.  If a 
biomarker passes this test, researchers must design further clinical trials to evaluate the 
use of the biomarker or panel in order to determine whether or not it can stratify risk 
(Paczesny et al. 2009), guide interventions (Paczesny et al. 2013), or perform in different 
conditions than demonstrated in the discovery or validation set (Paczesny et al. 2010; 
Ponce et al. 2014).  Ideally, a biomarker that speaks to the heart of a disease process 
should be able to perform in multiple centers in various settings (Addona et al. 2009).   
Despite the concerns and difficulties in biomarker discovery, of which there are 
many, biomarker panels must be developed for chronic GVHD.  That is to say that 
various serum/plasma, and potentially urine and saliva, biomarkers must be found for the 
various manifestations of chronic GVHD.  The best bet for identifying biomarkers in 
these fluids is to leverage mature discovery technologies, such as LC-MS/MS proteomics 
workflows to search for proteins with differing concentrations in the setting of classic 
chronic GVHD.   
After identification of likely 10-100s of protein concentrations that vary at least two-
fold in the disease state as compared to non-disease controls, a researcher with clinical 
experience, knowledge of immunology and the natural history and pathogenesis of 
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chronic GVHD must select one or more potential biomarkers for validation (Paczesny et 
al. 2009).  Ideally there will already be a developed and well-characterized antibody for 
the candidate biomarkers that can be used in either singlet or multiplexed immunoassays 
(Rozmus and Schultz 2011).  Validation studies must prove that the biomarker can 
predict the development of clinical signs and symptoms of the disease, and ideally, 
potential responsiveness to treatment, although this is largely a goal for further clinical 
trials. 
The forthcoming proposal for research will discuss in more detail the target organs in 
chronic GVHD that will be mined for biomarkers.  It will also determine the appropriate 
sample source to assay for each target organ as well as the development of a discovery 
set.  In addition it will explain, in more detail, the proteomics tool best suited to analyze 
the discovery set, i.e., the intact protein analysis system, which has been used in various 
biomarker discovery experiments in acute and chronic GVHD (Ferrara et al. 2011; 
Paczesny et al. 2010; Devic et al. 2014).  Appropriate experiments to validate the 
enhanced expression or down-regulation of candidate biomarkers in the tissue of interest 
must be performed, then a larger validation set should be used to determine the 
specificity and sensitivity of the biomarker in determining the presence of organ-specific 
chronic GVHD.  In addition, this validation set can be tested to statistically determine if 
concentrations of the biomarker can predict response to treatment and stratify risk, 
independently of pre-existing conditions and independent of NIH consensus criteria 
scores of chronic GVHD (Paczesny et al. 2010).  After these experiments are completed, 
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further clinical trials can be designed to test the the biomarker in specific transplant 
conditions and populations, and again examine, this time a priori, the significance and 
clinical utility of the biomarker, to determine if changing clinical practice based on 
biomarker signal can help reduce morbidity and mortality of organ-specific chronic 
GVHD.   
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PROPOSAL 
A number of studies have demonstrated that researchers are able to identify candidate 
biomarkers from saliva (Devic et al. 2014), urine (Beretov et al. 2014), skin (Paczesny et 
al. 2010), and blood (Paczesny et al. 2009).  Since chronic GVHD does not manifest 
principally in one anatomic area, and generally presents in multiple target organs, it 
seems that the most useful source of sample for the discovery experiment should be either 
blood, skin, liver, lungs, or mucosa (Jacobsohn et al. 2012).  The sample tissue/fluid for 
the discovery set can be further parsed arrow down our by considering the relative impact 
of the different types of chronic GVHD, and the current candidate biomarkers being 
evaluated for chronic GVHD.   
Recently, Devic published a paper identifying candidate biomarkers for oral / 
gastrointestinal (mucosal) chronic GVHD (Devic et al. 2014).  These candidate 
biomarkers , IL-1 receptor antagonist and cystatin B, showed decreased expression in 
patients with active oral chronic graft-versus-host disease and were validated using 
enzyme-linked immunosorbant assays (Devic et al. 2014).  These recent findings suggest 
that we should look elsewhere for a candidate biomarker in order to give clinicians 
biomarkers for other end organ chronic GVHD.   
The skin is the most common location of chronic GVHD and has a high hazard ratio 
indicating it contributes significantly to non-relapse morbidity and mortality(Wingard et 
al. 1989; Goerner et al. 2002).  Examples of clinical manifestation of skin chronic GVHD 
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are shown in Figure 3.  Common manifestations include cutaneous and sclerotic 
pathology (Jacobsohn et al. 2012). 
A       B 
          
 
Figure 3: Clinical manifestation of cutaneous and sclerotic chronic graft versus host 
disease. (A) Polkioderma - Polkiodermatous changes, mottled pigmentation and 
erythema present.(B) Cutaneous – Lichen-planus like pathology, papules and plaques 
present on trunk and extremities.  Adapted from (Cohen 2015) 
 
A recent study has validated the NIH composite 0-3 score in patients with cutaneous skin 
chronic GVHD, dismissing the clinical utility of most other scales.  The study assessed 
the ability of a number of clinical tools to predict non-relapse mortality, and physician 
and patient perception of skin chronic GVHD progression.  The NIH composite 0-3 score 
considers the extent of skin involvement, symptoms and presence of sclerotic features.  A 
score of 0 means that the patient is asymptomatic.  A score of 1 indicates the absence of 
sclerotic features and body surface area coverage of less than 18%.  A score of 2 
indicates either the presence of sclerotic features or 19-50% body surface area coverage.  
Finally a score of 3 indicates either greater than 50% body surface area coverage, or deep 
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sclerotic features, or impaired mobility, ulceration or severe pruritis (Filipovich et al. 
2005).  The study found a strong correlation between the score and non-relapse mortality, 
shown in Figure 4 (Jacobsohn et al. 2012). Other groups have identified acute GVHD 
markers in the skin, indicating that it is feasible to search for tissue specific markers in 
the plasma or serum of patients (Paczesny et al. 2010).   
 
 
Figure 4:  Overall survival and non-relapse mortality by NIH composite 0-3 score 
skin chronic graft versus host disease. 458 patients enrolled in this study to assess the 
ability of various clinical instruments to predict overall survival and non-relapse 
mortality in skin manifestations of chronic graft versus host disease. 
(A) Overall survival (y-axis) plotted against months since enrollment in study, each curve 
represents patients score at baseline.  Grade 3 significantly associated with higher 
mortality and non-relapse mortality.  (B) Cumulative incidence of non-relapse mortality 
(y-axis) plotted against months since enrollment in study.   Adapted from (Jacobsohn et 
al. 2012). 
Chronic GVHD also manifests commonly in the lungs, as previously stated, with up 
to 50% of patients who develop chronic GVHD exhibiting obstructive or restrictive 
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changes (Jacobsohn et al. 2012).  Long term survivors of allogeneic hematopoietic stem 
cell transplant exhibiting pulmonary dysfunction, and full-blown bronchiolitis obliterans 
have a 15.1-fold increased risk of late mortality when comparted to the general 
population (Bhatia et al. 2007).  Bonafide lung chronic GVHD, biopsy-proven 
bronchiolitis obliterans affects about 6% of allogeneic hematopoietic stem cell transplant 
patients, but has a five year survival of 13% (Williams et al. 2009), slightly lower than 
the general diagnosis of severe chronic GVHD at 15% (S. J. Lee and Flowers 2008).  As 
previously stated, many patients show clinical signs and symptoms of pulmonary 
dysfunction, however only a small portion of this subset of patients develops either type 
of bronchiolitis obliterans.  Because of this disparity, all patients who have undergone 
allogeneic transplant should be screened according to the diagnostic workup and clinical 
care algorithm similar to the recommendations of Hildebrandt, shown in Figure 5 
(Hildebrandt et al. 2011). 
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Figure 5: Diagnosis, work up and treatment of lung injury following allogeneic 
hematopoietic stem cell transplant. Pulmonary function test screening is recommended 
3, 6, 9, 12, 18 and 24 months after allogeneic hematopoietic stem cell transplant and then 
once per year.  Clinical decisions are made based on radiologic and pathology samples 
taken from lung lavage samples, which are not trivial to obtain.  Adapted from 
(Hildebrandt et al. 2011). 
Incorrect diagnosis of bronchiolitis obliterans, and the initiation of inhaled or 
systemic corticosteroids in the setting of infection, must be avoided in this setting.  A 
plasma biomarker could greatly aid this workflow and help guide decision-making at any 
of the bifurcation points found in the clinical workflow.  For example, a patient with non-
specific infiltrates discovered by computed tomography x-ray scan and impaired 
pulmonary function tests requires a lung biopsy in order to move forward with diagnosis 
and treatment.  Today, in cases where it is clinically difficult to obtain a biopsy, clinicians 
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must treat empirically.  A biomarker can help better clinical decision making at this key 
point and lead to better clinical outcomes (Paczesny 2013).  A biomarker might also be 
able to show which patients respond to front-line treatment for newly diagnosed airflow 
obstruction and decreased pulmonary function tests after allogeneic stem cell transplant.  
A clinical marker that could show patient response to treatment quickly could be used to 
modify clinical workflows – perhaps adding systemic to localized inhaled steroids in an 
effort to decrease plasma cell-mediated disposition of immunoglobins (Sarantopoulos et 
al. 2015).   
Now that the two organ targets of GVHD have been identified in order to search for 
biomarkers for skin and lung manifestations chronic GVHD, a discovery set must be 
acquired.  Depending on the strength of the treatment center’s general hematopoietic 
stem cell transplant sample collection protocol, the researcher should be able to identify 
approximately 10 heparinized plasma samples from patients who have undergone 
allogeneic hematopoietc stem cell transplants without developing either type of GVHD; 
these samples will serve as the control group. The researcher should also be able to 
identify 10 heparinized plasma samples for patients who have developed either single 
organ system isolated, biopsy-proven severe chronic GVHD of either the skin or lung, in 
which case 5 samples from each condition should be utilized, or samples from patients 
exhibiting both pathologies may be used.   
 One factor that should be controlled for is the sample quality, that is to say the length 
of time in storage, and number of freeze-thaws from -80
0
C (Keustermans et al. 2013).  
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Other factors that should be considered are the intensity of the conditioning regimen 
(myeloablative or non-myeoloabative), patient age, and the number of unrelated donors 
in each group (Paczesny et al. 2010).  In particular, the control group needs to be matched 
for pre-transplant lung infections, including colonization with Candida and other fungi, 
as well as bacterial infections in patients with severe lung chronic GVHD, so that the 
study does not conflate markers of bacterial and fungal damage to the lungs as being a 
marker of B cell-mediated chronic GVHD.  It also makes sense to control for the cell 
source and relevant manipulations.  Indication for transplant should not be a concern. 
Once the discovery set has been established, and the appropriate samples identified, 
they should be analyzed using a proteomic discovery tool.  A top-down proteomics 
workflow has some advantages when compared to an easier to execute bottom-up, or 
shotgun proteomics approach.  Top-down proteomics workflows have the advantage of 
being able to identify and discriminate between various isoforms of proteins, but are 
technically more complex than bottom-up approaches, and have difficulty identifying 
larger proteins (Han et al. 2006).  There is a workflow that relies on extensive 
fractionation of the starting sample called intact-protein analysis system, that bridges 
some of the gaps between these two approaches.  It has been successfully used in a 
number of GVHD biomarker discovery sets, and will serve as our discovery method in 
this proposal. (Paczesny et al. 2010; Ferrara et al. 2011; Wang et al. 2005) 
The intact-protein analysis system, developed by Wang, depletes the most abundant 
plasma proteins and allows us to assay the concentrations of lower abundance plasma 
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proteins (Wang et al. 2005).  When coupled with elements from Faca’s work (Faca et al. 
2006), the system becomes more robust and suited to purpose (Simpson and Greening 
2011). Briefly, the protocol used in the seminal 2005 study relies on a tripartite 
separation.  The samples should be pooled according to condition, then immuno-depleted 
of the most abundant plasma proteins using high performance liquid chromatography.  
Cysteine residues are then labeled with either light or heavy acrylamide isotypes 
according to the seminal work of Faca et al. (Faca et al. 2006).  Then, proteins are 
separated by charge and hydrophobicity, then by molecular mass, followed by 
interrogation by mass spectrometric analysis (Wang et al. 2005).  The separations are 
performed off line.  Liquid-based isoelectric focusing separates the proteins by isoelectric 
point; proteins that have a similar isoelectric point co-elute in fractions according to the 
pH at which they carry no charge (Moritz and Simpson 2005).  This procedure is 
followed by reverse phase high performance liquid chromatography, which relies on a 
hydrophobic stationary phase and a polar aqueous phase.  Thus, hydrophilic proteins are 
eluted in the first fractions off the column, and hydrophobic fractions are eluted after the 
addition of a non-polar mobile phase such as acetonitrile (Wang et al. 2005).  The final 
separation in this protocol is by mass, using sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis.  After separation by mass, protein expression is quantitatively visualized, 
by measuring the fluorescence of the cyanine dyes used to label the samples by condition 
earlier in the workflow (Tannu and Hemby 2006). 
  
33 
 
Proteins exhibiting differential expression between the two conditions are excised 
from the gels, washed, digested and analyzed via high performance liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) (Wang et al. 2005).  The 
spectra from each HPLC MS/MS run are analyzed for sequence matching.  Previous 
studies have reported that some proteins can be inadequately separated by hydrophobicity 
and there may be some overlap in this reverse phase chromatography separation (Wang et 
al. 2005).  After this has been taken into account, the identity of approximately 10-100 
proteins in the micromolar to fentomolar, biologically relevant range that vary 
significantly in concentration between conditions will have been identified, with a false 
discovery rate of 5% (Paczesny 2013).   
After execution of the discovery set and analysis of the mass spectrometry data, 
approximately 10 to 100 candidate spectra should have been identified that are selectively 
enriched in one condition or the other (Ferrara et al. 2011; Paczesny et al. 2010).  These 
candidate spectra are mapped to a sequence database and protein identities are inferred 
through this mapping process.  There is a now well-established false discovery rate of 5% 
in proteomic and microarray studies (Pawitan et al. 2005).  A literature search, pathway 
analysis, the availability of immunoassays for validation studies, and in this case, 
expression in the tissue of interest using the human protein atlas (Berglund et al. 2008), 
help guide the selection of appropriate candidates for validation studies (Paczesny et al. 
2010).     
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Once researchers have selected the candidate proteins, it is essential to ascertain that 
the candidate biomarkers of interest are expressed preferentially in the appropriate tissue 
and in the direction indicated by the discovery set.  For example, if the candidate 
biomarker is up-regulated in the pathological condition, the biomarker should be 
preferentially expressed in tissue sections from patients exhibiting pathology as compared 
with matched specimens from disease-free control patients (Paczesny et al. 2010; Ferrara 
et al. 2011).  Two small immunohistochemistry experiments should be run with 
appropriate controls.  Tissue samples from age-matched patients who have not shown any 
signs of skin acute or chronic GVHD, but have exhibited documented drug reactions or 
skin manifestations of diseases other than acute or chronic GVHD should be compared 
with tissue samples from patients who have exhibited biopsy-proven skin chronic GVHD.  
The researcher will assay the tissue sections for the candidate biomarker and it should be 
present in the subcutaneous tissue, down to the dermis of affected patients.  Tissue 
samples from cadaverous lungs from patients diagnosed with bronchiolitis obliterans and 
age-matched controls should be assayed for a candidate biomarker of lung chronic 
GVHD, and the biomarker should be preferentially expressed in this tissue when 
compared to the tissue from age-matched patients who have not shown any signs of 
bronchiolitis obliterans and have expired due to infection of the lung tissue with fungi or 
bacteria. 
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After the candidate biomarker has exhibited appropriate and selective up-regulation 
or down-regulation in the target tissues, validation sets must be established to determine 
whether or not a candidate biomarker has diagnostic and/or prognostic value.   
In order to execute this next step of a biomarker identification study, a researcher will 
again rely on a strong institutional or multi-institutional banking study that can provide 
heparinized plasma samples from a large cohort of patients.  Ideally these samples will 
have been collected fairly recently at regular intervals during the transplant period and at 
key events during the patient’s post-transplant experience (Ferrara et al. 2011).  Stability 
studies should be executed to ensure that the levels of the candidate biomarker are stable 
over the time period of the study; e.g., if plasma levels of the candidate biomarker are 
stable for two years, samples greater than two years old should not be included in the 
validation set (Parkitny et al. 2013).  Furthermore, the general rule of thumb is that 
samples should not have been thawed and aliquoted for other studies more than twice.  If 
samples cannot be obtained for a patient at several time points, they should not be 
included in analysis.  For the purpose of a validation study, samples should be handled 
consistently across institutions and shipped to one institution to perform the biomarker 
assay itself.   
Several studies have measured levels of biomarker at the onset of symptoms 
(Paczesny et al. 2009; Ferrara et al. 2011), as many hematopoietic stem cell transplant 
centers sample collection protocols require taking samples at or around the time of major 
changes in patient status.  It might also be worthwhile to look for changes in the 
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biomarker in samples relatively close, and prior, to diagnosis, because a biomarker with a 
strong positive predictive value could be used in prospective studies to initiate treatment 
prior to symptoms developing (Paczesny et al. 2013). 
In many validation studies, patients meeting some minimum criteria are all included 
for analysis.  Generally these criteria include having available samples, and having had 
similar GVHD prophylaxis.  These analyses are generally restricted to either an adult or 
pediatric patient population but do not have to be if it can be proven that introduction of 
this variable will not bias the data (Ferrara et al. 2011).  Summary characteristics of all 
patients potentially included in the study should be determined prior to acquiring samples 
and assaying them for the candidate biomarkers of interest in order to show that the study 
is not a priori biased and is adequately powered to detect differences between outcomes.   
For this particular study it will be exceedingly important to have many well-
powered groups, which means it will likely require samples obtained from multiple 
hematopoietic stem cell transplant centers.  These groups must be painstakingly parsed 
by chart review to determine their GVHD status i.e.,what NIH criteria they met, 
e.g.,acute, chronic, overlap, along with grading and staging (Baird et al. 2013), GVHD 
prophylaxis, GVHD treatment (i.e. systemic corticosteroid treatment), underlying 
disease, conditioning regimen, cell source and manipulation. 
Ferrara required massive power; there were 1,1014 patients in the validation sets 
for the biomarker, regenerating islet –derived 3 alpha (Ferrara et al. 2011). A large 
sample population may be easily obtained for patients who have exhibited skin chronic 
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GVHD from the biobank of just one major hematopoietic stem cell transplant center.  
However, due to the relative paucity of patients whom develop bronchiolitis obliterans, 
the biobanks of many hematopoietic stem cell transplant facilities will have to be 
explored in order to get a least a ten-fold increase in sample population from the 
discovery set.  The candidate biomarkers should be able to diagnose or predict the onset 
of disease (minimally) in both patients who exhibit tissue-specific chronic GVHD and, if 
the biomarker is a marker of effector cell response, not tissue-specific chronic graft-
versus-host mediated damage, also in patients who exhibit other organ chronic GVHD.  
A candidate biomarker should be selective to the condition of interest.  In the case of skin 
chronic GVHD, samples from control groups, including patients who developed drug 
rashes and other skin manifestations shown not to be chronic GVHD, patients who did 
not develop skin chronic GVHD, and patients who have chronic GVHD in other end 
organs, should have a significantly different level of expression than the target condition.  
Similarly, in the case of bronchiolitis, the biomarker should be able to discriminate 
between the target condition and control groups.   
In addition to determining that the candidate biomarker can discriminate between 
the above-mentioned groups in the global set of patients, it will be worthwhile to 
statistically examine the effect of other criteria on candidate biomarker levels.  It would 
not be surprising to see that previous GVHD (acute or chronic) treatment with 
corticosteroids affects biomarker levels, or that GVHD at different stages affects the 
levels of biomarkers (Berger et al. 2013).  Additionally, the level of a biomarker at the 
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time of diagnosis might correspond to the NIH consensus criteria grade of skin or lung 
chronic GVHD at time of diagnosis.   
Regardless of statistically significant differences between groups as determined 
using parametric or non-parametric means, the most important test of a biomarker is how 
it performs in non-parametric receiver-operator characteristic and area under the curve 
analysis.  These methods, developed in the Second World War, yield optimal cut off 
points for biomarkers and help determine the negative and positive predictive values of 
the biomarker for the specific disease condition (Baker 2003).  The curve plots the true 
positive rate (sensitivity) against the false positive rate (1 – specificity).  The area under 
the curve summarizes the ability of the test to discriminate between the two conditions, in 
our case, the presence or absence of skin chronic GVHD.  The area under the curve will 
range from a value of 1, indicating that the test perfectly predicts the presence or absence 
of the condition, to 0.5 indicating that the test has no ability to discriminate between the 
two conditions.   In Figure 6, a set of receiver-operator characteristic curve from an acute 
GVHD are shown.  In this study, a panel of biomarkers was analyzed to determine which 
biomarker(s) could diagnose acute lower gastro-intestinal GVHD in a series of patients 
who had post hematopoietic stem cell transplant diarrhea.  The candidate biomarker 
displayed similar specificity and sensitivity and area under the curve to the four 
biomarker panel (Ferrara et al. 2011).   
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Figure 6: Receiver-Operator Characteristic curve for patients exhibiting post 
hematopoietic stem cell transplant diarrhea. Biomarkers were analyzed for 204 
patients whom had diarrhea post hematopoietic stem cell transplant.  The biomarker, 
regenerating islet-derived 3 alpha, is in thick dark blue, a panel of all biomarkers 
measured is in thick black.  Other, inferior biomarkers are in different colors.  The area 
under the curve for the biomarker regenerating islet-derived 3 alpha is 0.80, indicating 
that it is a useful biomarker.  Adapted from Ferrara et al. 2011).  
Ideally the biomarkers identified via the discovery set will have a sensitivity and 
specificity greater than that of the current gold standard of diagnosis, biopsy of the 
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affected tissue, i.e., the area under the curve for the identified biomarkers indicates 
correlation with a correct disease diagnosis with greater discrimination than biopsy.   
The most important characteristic of a biomarker used for diagnosis is either a 
high positive predictive value or a high negative predictive value – of course, an ideal 
biomarker has both characteristics, but it is very unlikely that such a biomarker exists for 
an iatrogenic complex disease in the setting of another complex disease.  A high positive 
predictive value indicates that when a biomarker indicates the disease or condition is 
present that it is highly accurate or “true”; that is to say the biomarker has a low false 
positive rate.  A high negative predictive value indicates that when a biomarker indicates 
a disease is not present that it is also highly accurate or “true”, but in this case the 
biomarker has a low false negative rate.  Generally a useful biomarker has one of these 
two characteristics (Hanash, Pitteri, and Faca 2008).    
Biomarkers can also be used to stratify risk.  Several studies have shown that a 
high or low (depending on the direction that indicates disease) biomarker level can 
stratify risk (Ferrara et al. 2011), much like the consensus NIH grading and staging of 
chronic GVHD (Baird et al. 2013) predicting non-relapse mortality over an appropriate 
time scale based on other criteria .  This analysis could be easily conducted on a group of 
patients that have skin or lung chronic GVHD, using the statistical methods established 
by Fine (Fine and Gray 1999).  Several studies have used acute GVHD biomarkers, alone 
or in a panel, to determine and predict treatment outcomes.  Levine showed that a 6-
protein biomarker panel, including the biomarkers tumor necrosis factor receptor-1, 
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Interleukin-2 receptor-alpha, Interleukin-8, hepatocyte growth factor, elafin, and 
regenerating islet–derived 3 alpha, were able to predict non-responders to treatment at 28 
days post initiation of therapy and mortality at day 180 from onset (Levine et al. 2012). 
A biomarker has greater clinical utility if it can predict response to treatment.  
Therefore appropriate non-parametric statistical analysis should be completed to 
determine whether high or low concentrations of biomarker within the affected group 
exhibit predictive value with respect to response to treatment, and predict the maximum 
clinical stage and grade of  end-organ chronic graft-versus-host disease (MacMillan, 
DeFor, and Weisdorf 2010).   
After the biomarker has been validated, and has exhibited a strong positive or 
negative predictive value, as well as an ability to stratify risk and predict response to 
treatment, follow-up prospective clinical trials must be initiated to truly prove the clinical 
utility of the biomarker.   
We can utilize a model provided by Paczensy, shown in Figure 7 to evaluate the 
clinical utility of the biomarker in a phase two trial (Paczesny 2013).  Briefly, in the 
intervention group, biomarker concentration can be used, either alone or in combination 
with established methods, to stratify the risk of non-relapse mortality in this subset of 
patients.  Patients in the higher risk group can receive a best-in-class treatment 
prospectively, e.g. steroids plus a secondary agent, potentially extra corporeal 
photopheresis (Heshmati 2010), monoclonal antibody or other intervention (Choi and 
Reddy 2014).  Patients in the control group receive the standard of care.  The outcomes of 
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patients in both groups can be tracked, and hopefully the tailored interventions to 
biomarker levels can be used to decrease non-responsiveness to treatment and decrease 
morbidity and mortality in this vulnerable population of patients.  
In the case of skin chronic GVHD, steroids plus a secondary agent as selected from a 
list of approved agents at a given hematopoietic stem cell transplant center, potentially 
extra corporeal photopheresis (Heshmati 2010), monoclonal antibody or other 
intervention (Choi and Reddy 2014).  Patients in the control group receive the standard of 
care.  The outcomes of patients in both groups can be tracked, and hopefully the tailored 
interventions to biomarker levels can be used to decrease non-responsiveness to treatment 
and decrease morbidity and mortality in this vulnerable population of patients.   A similar 
protocol can be used in cases of lung chronic GVHD, wherein patients who exhibit 
abnormal pulmonary function tests, and abnormal findings on computerized tomography 
x-ray scans of the lungs at any point post-transplant, can be assayed for biomarker 
concentrations, and based on the concentration of the biomarker, can be assigned to either 
a two steroid, topical (inhaled) and systemic, or one steroid, topical (inhaled) regimen to 
treat their disease.   
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Figure 7: Fundamental design of a randomized trial to evaluate biomarker utility. 
Patients are randomized into two groups, those who receive the standard of care, and 
those for whom the validated biomarker is measured.  Patients in the biomarker group 
receive and appropriate level of intervention, none, steroid, or best in class treatment (two 
agents) depending on their relative risk.  The outcome variables are non relapse mortality, 
overall survival and the like.  
 
This type of phase two clinical trial can be executed at a number of hematopoietic 
stem cell transplant centers.  Furthermore, in the case of chronic lung GVHD, stratified 
biomarker concentration can be used to determine which patients will respond to either 
standard or enhanced treatment strategies and may be used to help fast-track some of 
these patients to acquire a lung transplant (Cheng et al. 2014).  In addition to these 
clinical trials, the validated biomarkers may be used as part of a chronic GVHD 
biomarker panel to determine the relative risk of developing chronic GVHD in various 
allogeneic stem cell transplant settings, including the use of different sources of 
hematopoietic stem cell grafts (Ponce et al. 2014), including manipulated grafts, and in 
reduced intensity conditioning (Pollack et al. 2009), and haplo-identical hematopoietic 
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stem cell transplant, which is rapidly becoming an option at many first tier hematopoietic 
stem cell transplant facilities (Ballen et al. 2012). 
CONCLUSION 
In conclusion, biomarker discovery validation and detection may be accomplished 
leveraging proteomic techniques.  These protein biomarkers speak directly to the 
pathogenesis of allo-reactivity in real time.  Top-down and bottom-up mass spectrometry 
discovery techniques have identified many biomarkers for diverse conditions including 
both chronic (Devic et al. 2014) and acute GVHD (Paczesny et al. 2010) that would have 
most likely not been identified using hypothesis-driven research (Paczesny 2013).  After 
validation under standard conditions, these biomarkers must be validated to determine 
their utility in diverse settings, including reduced intensity allogeneic hematopoietic stem 
cell transplant, and with various cell sources (Ponce et al. 2014).  The goals of biomarker 
discovery in chronic GVHD is to be able to determine which patients will develop the 
condition, so as not to treat patients who have other skin conditions that may respond 
poorly to steroids or other treatment modalities increasing their risk of mortality, and to 
determine which patients will be non-responsive to the standard of care treatment, so that 
they may be treated more aggressively.  Ultimately, the establishment of a repertoire of 
chronic GVHD biomarkers will help usher in an era of personalized medicine, and help 
determine the best intervention for each individual patient.  
 
  
  
45 
 
REFERENCES 
 
Addona, Terri A., Susan E. Abbatiello, Birgit Schilling, Steven J. Skates, D. R. Mani, David M. 
Bunk, Clifford H. Spiegelman, et al. 2009. “Multi-Site Assessment of the Precision and 
Reproducibility of Multiple Reaction Monitoring-Based Measurements of Proteins in 
Plasma.” Nature Biotechnology 27 (7): 633–41. doi:10.1038/nbt.1546. 
Atarod, Sadaf, and Anne Mary Dickinson. 2013. “MicroRNAs: The Missing Link in the Biology 
of Graft-Versus-Host Disease?” Frontiers in Immunology 4: 420. 
doi:10.3389/fimmu.2013.00420. 
Baird, Kristin, Seth M. Steinberg, Lana Grkovic, Drazen Pulanic, Edward W. Cowen, Sandra A. 
Mitchell, Kirsten M. Williams, et al. 2013. “National Institutes of Health Chronic Graft-
versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring 
Correlate with Established Indicators of Disease Severity and Prognosis.” Biology of 
Blood and Marrow Transplantation 19 (4): 632–39. doi:10.1016/j.bbmt.2013.01.013. 
Baker, Stuart G. 2003. “The Central Role of Receiver Operating Characteristic (ROC) Curves in 
Evaluating Tests for the Early Detection of Cancer.” Journal of the National Cancer 
Institute 95 (7): 511–15. doi:10.1093/jnci/95.7.511. 
Bayraktar, Ulas D., Qaiser Bashir, Muzaffar Qazilbash, Richard E. Champlin, and Stefan O. 
Ciurea. 2013. “Fifty Years of Melphalan Use in Hematopoietic Stem 
Cell Transplantation.” Biology of Blood and Marrow Transplantation: Journal of the 
American Society for Blood and Marrow Transplantation 19 (3): 344–56. 
doi:10.1016/j.bbmt.2012.08.011. 
Beretov, Julia, Valerie C. Wasinger, Peter Schwartz, Peter H. Graham, and Yong Li. 2014. “A 
Standardized and Reproducible Urine Preparation Protocol for Cancer Biomarkers 
Discovery.” Biomarkers in Cancer 6: 21–27. doi:10.4137/BIC.S17991. 
Berger, M., E. Signorino, M. Muraro, P. Quarello, E. Biasin, F. Nesi, E. Vassallo, and F. Fagioli. 
2013. “Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 Following HSCT 
and Their Role as GVHD Biomarkers in Paediatric Patients.” Bone Marrow 
Transplantation 48 (9): 1230–36. doi:10.1038/bmt.2013.41. 
Berglund, Lisa, Erik Björling, Per Oksvold, Linn Fagerberg, Anna Asplund, Cristina Al-Khalili 
Szigyarto, Anja Persson, et al. 2008. “A Genecentric Human Protein Atlas for Expression 
Profiles Based on Antibodies.” Molecular & Cellular Proteomics 7 (10): 2019–27. 
doi:10.1074/mcp.R800013-MCP200. 
Berz, David, Elise M McCormack, Eric S Winer, Gerald A Colvin, and Peter J Quesenberry. 
2007. “Cryopreservation of Hematopoietic Stem Cells.” American Journal of 
Hematology 82 (6): 463–72. doi:10.1002/ajh.20707. 
Bochennek, K., R. Esser, T. Lehrnbecher, W. Glienke, S. Wehner, S. Erben, J. Soerensen, et al. 
2012. “Impact of Minimal Residual Disease Detection prior to Autologous Stem Cell 
  
46 
 
Transplantation for Post-Transplant Outcome in High Risk Neuroblastoma.” Klinische 
Pädiatrie 224 (3): 139–42. doi:10.1055/s-0031-1301334. 
Champlin, Richard, Elias Jabbour, Partow Kebriaei, Paolo Anderlini, Borje Andersson, and 
Marcos de Lima. 2011. “Allogeneic Stem Cell Transplantation for Chronic Myeloid 
Leukemia Resistant to Tyrosine Kinase Inhibitors.” Clinical Lymphoma, Myeloma & 
Leukemia 11 Suppl 1 (June): S96–100. doi:10.1016/j.clml.2011.03.028. 
Chaturvedi, Anil K, Troy J Kemp, Ruth M Pfeiffer, Angelique Biancotto, Marcus Williams, 
Stella Munuo, Mark P Purdue, et al. 2011. “Evaluation of Multiplexed Cytokine and 
Inflammation Marker Measurements: A Methodologic Study.” Cancer Epidemiology 
Biomarkers & Prevention 20 (9): 1902–11. doi:10.1158/1055-9965.EPI-11-0221. 
Choi, Sung Won, and Pavan Reddy. 2014. “Current and Emerging Strategies for the Prevention 
of Graft-versus-Host Disease.” Nature Reviews. Clinical Oncology 11 (9): 536–47. 
doi:10.1038/nrclinonc.2014.102. 
Clift, R. A., C. D. Buckner, F. R. Appelbaum, S. I. Bearman, F. B. Petersen, L. D. Fisher, C. 
Anasetti, P. Beatty, W. I. Bensinger, and K. Doney. 1990. “Allogeneic Marrow 
Transplantation in Patients with Acute Myeloid Leukemia in First Remission: A 
Randomized Trial of Two Irradiation Regimens.” Blood 76 (9): 1867–71. 
Cohen, Edward P. 2015. “Cutaneous Manifestations of Graft-versus-Host Disease (GVHD).” 
Accessed February 9. http://www.uptodate.com/contents/cutaneous-manifestations-of-
graft-versus-host-disease-
gvhd?source=search_result&search=skin+chronic+graft+versus+host+disease&selectedT
itle=1~3. 
Coron, Emmanuel, Valerie Laurent, Florent Malard, Marc Le Rhun, Patrice Chevallier, Thierry 
Guillaume, Jean-François Mosnier, Jean-Paul Galmiche, and Mohamad Mohty. 2014. 
“Early Detection of Acute Graft-versus-Host Disease by Wireless Capsule Endoscopy 
and Probe-Based Confocal Laser Endomicroscopy: Results of a Pilot Study.” United 
European Gastroenterology Journal 2 (3): 206–15. doi:10.1177/2050640614529283. 
“Definition of Biomarker - NCI Dictionary of Cancer Terms.” 2015. National Cancer Institute. 
Accessed February 3. http://www.cancer.gov/dictionary. 
Devic, Ivana, Min Shi, Mark M. Schubert, Michele Lloid, Kenneth T. Izutsu, Catherine Pan, 
Melody Missaghi, et al. 2014. “Proteomic Analysis of Saliva from Patients with Oral 
Chronic Graft-Versus-Host Disease.” Biology of Blood and Marrow Transplantation 20 
(7): 1048–55. doi:10.1016/j.bbmt.2014.03.031. 
Faca, Vitor, Marc Coram, Doug Phanstiel, Veronika Glukhova, Qing Zhang, Matthew 
Fitzgibbon, Martin McIntosh, and Samir Hanash. 2006. “Quantitative Analysis of 
Acrylamide Labeled Serum Proteins by LC−MS/MS.” Journal of Proteome Research 5 
(8): 2009–18. doi:10.1021/pr060102+. 
  
47 
 
Fermand, J. P., P. Ravaud, S. Chevret, M. Divine, V. Leblond, C. Belanger, M. Macro, et al. 
1998. “High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation 
in Multiple Myeloma: Up-Front or Rescue Treatment? Results of a Multicenter 
Sequential Randomized Clinical Trial.” Blood 92 (9): 3131–36. 
Ferrara, James L. M., Andrew C. Harris, Joel K. Greenson, Thomas M. Braun, Ernst Holler, 
Takanori Teshima, John E. Levine, et al. 2011. “Regenerating Islet-Derived 3-Alpha Is a 
Biomarker of Gastrointestinal Graft-versus-Host Disease.” Blood 118 (25): 6702–8. 
doi:10.1182/blood-2011-08-375006. 
Filipovich, Alexandra H., Daniel Weisdorf, Steven Pavletic, Gerard Socie, John R. Wingard, 
Stephanie J. Lee, Paul Martin, et al. 2005. “National Institutes of Health Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease: I. Diagnosis and Staging Working Group Report.” Biology of Blood and 
Marrow Transplantation 11 (12): 945–56. doi:10.1016/j.bbmt.2005.09.004. 
Fine, Jason P., and Robert J. Gray. 1999. “A Proportional Hazards Model for the Subdistribution 
of a Competing Risk.” Journal of the American Statistical Association 94 (446): 496–
509. doi:10.1080/01621459.1999.10474144. 
Goerner, Martin, Theodore Gooley, Mary E. D Flowers, Keith M Sullivan, Hans-Peter Kiem, 
Jean E Sanders, Paul J Martin, and Rainer Storb. 2002. “Morbidity and Mortality of 
Chronic GVHD after Hematopoietic Stem Cell Transplantation from HLA-Identical 
Siblings for Patients with Aplastic or Refractory Anemias.” Biology of Blood and 
Marrow Transplantation 8 (1): 47–56. doi:10.1053/bbmt.2002.v8.pm11858190. 
Greinix, Hildegard T., Zoya Kuzmina, Roman Weigl, Ulrike Körmoczi, Arno Rottal, Daniel 
Wolff, Mateja Kralj, et al. 2014. “CD19+CD21low B Cells and CD4+CD45RA+CD31+ 
T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease.” Biology of 
Blood and Marrow Transplantation. Accessed December 22. 
doi:10.1016/j.bbmt.2014.11.010. 
Hanash, Samir M., Sharon J. Pitteri, and Vitor M. Faca. 2008. “Mining the Plasma Proteome for 
Cancer Biomarkers.” Nature 452 (7187): 571–79. doi:10.1038/nature06916. 
Han, Xuemei, Aaron Aslanian, and John R. Yates. 2008. “Mass Spectrometry for Proteomics.” 
Current Opinion in Chemical Biology 12 (5): 483–90. doi:10.1016/j.cbpa.2008.07.024. 
Han, Xuemei, Mi Jin, Kathrin Breuker, and Fred W. McLafferty. 2006. “Extending Top-Down 
Mass Spectrometry to Proteins with Masses Greater Than 200 Kilodaltons.” Science 314 
(5796): 109–12. doi:10.1126/science.1128868. 
Heshmati, Farhad. 2010. “Extra Corporeal Photo Chemotherapy (ECP) in Acute and Chronic 
GVHD.” Transfusion and Apheresis Science: Official Journal of the World Apheresis 
Association: Official Journal of the European Society for Haemapheresis 43 (2): 211–15. 
doi:10.1016/j.transci.2010.07.017. 
  
48 
 
Jacobsohn, David A., Brenda F. Kurland, Joseph Pidala, Yoshihiro Inamoto, Xiaoyu Chai, Jeanne 
M. Palmer, Sally Arai, et al. 2012. “Correlation between NIH Composite Skin Score, 
Patient-Reported Skin Score, and Outcome: Results from the Chronic GVHD 
Consortium.” Blood 120 (13): 2545–52; quiz 2774. doi:10.1182/blood-2012-04-424135. 
Keustermans, Genoveva C. E., Sanne B. E. Hoeks, Jenny M. Meerding, Berent J. Prakken, and 
Wilco de Jager. 2013. “Cytokine Assays: An Assessment of the Preparation and 
Treatment of Blood and Tissue Samples.” Methods, Cytokine Methods, 61 (1): 10–17. 
doi:10.1016/j.ymeth.2013.04.005. 
Körbling, Martin, and Emil J. Freireich. 2011. “Twenty-Five Years of Peripheral Blood Stem Cell 
Transplantation.” Blood 117 (24): 6411–16. doi:10.1182/blood-2010-12-322214. 
Krejci, Marta, Michael Doubek, Yvona Brychtova, Olga Stehlikova, Jana Chovancova, Boris 
Tichy, Hana Skuhrova Francova, et al. 2013. “Fludarabine with Cytarabine Followed by 
Reduced-Intensity Conditioning and Allogeneic Hematopoietic Stem Cell 
Transplantation in Patients with Poor-Risk Chronic Lymphocytic Leukemia.” Annals of 
Hematology 92 (2): 249–54. doi:10.1007/s00277-012-1579-y. 
Kuzmina, Zoya, Hildegard T. Greinix, Roman Weigl, Ulrike Körmöczi, Arno Rottal, Sophie 
Frantal, Sandra Eder, and Winfried F. Pickl. 2011. “Significant Differences in B-Cell 
Subpopulations Characterize Patients with Chronic Graft-versus-Host Disease–associated 
Dysgammaglobulinemia.” Blood 117 (7): 2265–74. doi:10.1182/blood-2010-07-295766. 
Lee, S.-E., B.-S. Cho, J.-H. Kim, J.-H. Yoon, S.-H. Shin, S.-A. Yahng, K.-S. Eom, et al. 2013. 
“Risk and Prognostic Factors for Acute GVHD Based on NIH Consensus Criteria.” Bone 
Marrow Transplantation 48 (4): 587–92. doi:10.1038/bmt.2012.187. 
Levine, John E., Brent R. Logan, Juan Wu, Amin M. Alousi, Javier Bolaños-Meade, James L. M. 
Ferrara, Vincent T. Ho, Daniel J. Weisdorf, and Sophie Paczesny. 2012. “Acute Graft-
versus-Host Disease Biomarkers Measured during Therapy Can Predict Treatment 
Outcomes: A Blood and Marrow Transplant Clinical Trials Network Study.” Blood 119 
(16): 3854–60. doi:10.1182/blood-2012-01-403063. 
MacMillan, Margaret L., Todd E. DeFor, and Daniel J. Weisdorf. 2010. “The Best Endpoint for 
Acute GVHD Treatment Trials.” Blood 115 (26): 5412–17. doi:10.1182/blood-2009-12-
258442. 
Marek, A., M. Stern, Y. Chalandon, M. Ansari, H. Ozsahin, T. Güngör, B. Gerber, et al. 2014. 
“The Impact of T-Cell Depletion Techniques on the Outcome after Haploidentical 
Hematopoietic SCT.” Bone Marrow Transplantation 49 (1): 55–61. 
doi:10.1038/bmt.2013.132. 
McCarthy, Philip L., and Theresa Hahn. 2013. “Strategies for Induction, Autologous 
Hematopoietic Stem Cell Transplantation, Consolidation, and Maintenance for 
Transplantation-Eligible Multiple Myeloma Patients.” ASH Education Program Book 
2013 (1): 496–503. doi:10.1182/asheducation-2013.1.496. 
  
49 
 
Mohty, Mohamad, and Anthony D. Ho. 2011. “In and out of the Niche: Perspectives in 
Mobilization of Hematopoietic Stem Cells.” Experimental Hematology 39 (7): 723–29. 
doi:10.1016/j.exphem.2011.05.004. 
Moon, Joon Ho, Sang Kyun Sohn, Anna Lambie, Laura Ellis, Nada Hamad, Jieun Uhm, Vikas 
Gupta, et al. 2014. “Validation of National Institutes of Health Global Scoring System for 
Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific 
Survival.” Biology of Blood and Marrow Transplantation 20 (4): 556–63. 
doi:10.1016/j.bbmt.2014.01.010. 
Morishima, Yasuo, Takehiko Sasazuki, Hidetoshi Inoko, Takeo Juji, Tatsuya Akaza, Ken 
Yamamoto, Yoshihide Ishikawa, et al. 2002. “The Clinical Significance of Human 
Leukocyte Antigen (HLA) Allele Compatibility in Patients Receiving a Marrow 
Transplant from Serologically HLA-A, HLA-B, and HLA-DR Matched Unrelated 
Donors.” Blood 99 (11): 4200–4206. 
Moritz, Robert L., and Richard J. Simpson. 2005. “Liquid-Based Free-Flow Electrophoresis–
reversed-Phase HPLC: A Proteomic Tool.” Nature Methods 2 (11): 863–73. 
doi:10.1038/nmeth1105-863. 
Murphy, Elizabeth A., Stacy Stickney Ferguson, Nancy Atieno Omondi, Lisa C. Getzendaner, 
James L. Gajewski, Gary A. Goldstein, John R. Wingard, J. Douglas Rizzo, Navneet S. 
Majhail, and Navneet S. Mahjail. 2010. “The National Marrow Donor Program’s 
Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing 
Barriers to Hematopoietic Cell Transplantation.” Biology of Blood and Marrow 
Transplantation: Journal of the American Society for Blood and Marrow Transplantation 
16 (2): 147–56. doi:10.1016/j.bbmt.2009.08.004. 
Ofran, Yishay, and Jerome Ritz. 2008. “Targets of Tumor Immunity after Allogeneic 
Hematopoietic Stem Cell Transplantation.” Clinical Cancer Research: An Official 
Journal of the American Association for Cancer Research 14 (16): 4997–99. 
doi:10.1158/1078-0432.CCR-08-0857. 
Paczesny, Sophie. 2013. “Discovery and Validation of Graft-versus-Host Disease Biomarkers.” 
Blood 121 (4): 585–94. doi:10.1182/blood-2012-08-355990. 
Paczesny, Sophie, Thomas M. Braun, John E. Levine, Jason Hogan, Jeffrey Crawford, Bryan 
Coffing, Stephen Olsen, et al. 2010. “Elafin Is a Biomarker of Graft-versus-Host Disease 
of the Skin.” Science Translational Medicine 2 (13): 13ra2. 
doi:10.1126/scitranslmed.3000406. 
Paczesny, Sophie, Oleg I. Krijanovski, Thomas M. Braun, Sung W. Choi, Shawn G. Clouthier, 
Rork Kuick, David E. Misek, et al. 2009. “A Biomarker Panel for Acute Graft-versus-
Host Disease.” Blood 113 (2): 273–78. doi:10.1182/blood-2008-07-167098. 
Paczesny, Sophie, Nisha Raiker, Sam Brooks, and Christy Mumaw. 2013. “Graft-versus-Host 
Disease Biomarkers: Omics and Personalized Medicine.” International Journal of 
Hematology 98 (3): 275–92. doi:10.1007/s12185-013-1406-9. 
  
50 
 
Parkitny, Luke, James H. McAuley, Patrick J. Kelly, Flavia Di Pietro, Barbara Cameron, and G. 
Lorimer Moseley. 2013. “Multiplex Cytokine Concentration Measurement: How Much 
Do the Medium and Handling Matter?” Mediators of Inflammation 2013: 1–13. 
doi:10.1155/2013/890706. 
Parks, Bryan A., Lihua Jiang, Paul M. Thomas, Craig D. Wenger, Michael J. Roth, Michael T. 
Boyne, Patricia V. Burke, Kurt E. Kwast, and Neil L. Kelleher. 2007. “Top-Down 
Proteomics on a Chromatographic Time Scale Using Linear Ion Trap Fourier Transform 
Hybrid Mass Spectrometers.” Analytical Chemistry 79 (21): 7984–91. 
doi:10.1021/ac070553t. 
Pawitan, Yudi, Stefan Michiels, Serge Koscielny, Arief Gusnanto, and Alexander Ploner. 2005. 
“False Discovery Rate, Sensitivity and Sample Size for Microarray Studies.” 
Bioinformatics 21 (13): 3017–24. doi:10.1093/bioinformatics/bti448. 
Pidala, Joseph, Jongphil Kim, Claudio Anasetti, Taiga Nishihori, Brian Betts, Teresa Field, and 
Janelle Perkins. 2011. “The Global Severity of Chronic Graft-versus-Host Disease, 
Determined by National Institutes of Health Consensus Criteria, Is Associated with 
Overall Survival and Non-Relapse Mortality.” Haematologica 96 (11): 1678–84. 
doi:10.3324/haematol.2011.049841. 
Ponce, Doris M., Patrick Hilden, Christen Mumaw, Sean M. Devlin, Marissa Lubin, Sergio 
Giralt, Jenna D. Goldberg, et al. 2014. “High Day 28 ST2 Levels Predict for Acute Graft-
versus-Host Disease and Transplant-Related Mortality after Cord Blood 
Transplantation.” Blood, January, blood – 2014–06 – 584789. doi:10.1182/blood-2014-
06-584789. 
Rozmus, Jacob, and Kirk R Schultz. 2011. “Biomarkers in Chronic Graft-versus-Host Disease.” 
Expert Review of Hematology 4 (3): 329–42. doi:10.1586/ehm.11.27. 
Sarantopoulos, Stefanie, Kristen E Stevenson, Haesook T Kim, Nazmim S Bhuiya, Corey S 
Cutler, Robert J Soiffer, Joseph H Antin, and Jerome Ritz. 2007. “High Levels of B-Cell 
Activating Factor in Patients with Active Chronic Graft-versus-Host Disease.” Clinical 
Cancer Research: An Official Journal of the American Association for Cancer Research 
13 (20): 6107–14. doi:10.1158/1078-0432.CCR-07-1290. 
Schütt, P., J. Passon, P. Ebeling, A. Welt, S. Müller, K. Metz, T. Moritz, S. Seeber, and M. R. 
Nowrousian. 2007. “Ifosfamide, Etoposide, Cytarabine, and Dexamethasone as Salvage 
Treatment Followed by High-Dose Cyclophosphamide, Melphalan, and Etoposide with 
Autologous Peripheral Blood Stem Cell Transplantation for Relapsed or Refractory 
Lymphomas.” European Journal of Haematology 78 (2): 93–101. doi:10.1111/j.1600-
0609.2006.00796.x. 
Servais, Sophie, Frédéric Baron, and Yves Beguin. 2011. “Allogeneic Hematopoietic Stem Cell 
Transplantation (HSCT) after Reduced Intensity Conditioning.” Transfusion and 
Apheresis Science: Official Journal of the World Apheresis Association: Official Journal 
of the European Society for Haemapheresis 44 (2): 205–10. 
doi:10.1016/j.transci.2011.01.019. 
  
51 
 
Shimoni, Avichai, and Arnon Nagler. 2002. “Non-Myeloablative Hematopoietic Stem Cell 
Transplantation (NST) in the Treatment of Human Malignancies: From Animal Models 
to Clinical Practice.” Cancer Treatment and Research 110: 113–36. 
Simpson, Richard J., and David W. Greening, eds. 2011. “Intact-Protein Analysis System for 
Discovery of Serum-Based Disease Biomarkers - Springer.” In . Methods in Molecular 
Biology 728. Humana Press. 
http://link.springer.com.ezproxy.bu.edu/protocol/10.1007/978-1-61779-068-3_4. 
Socié, Gérard, Judith Veum Stone, John R. Wingard, Daniel Weisdorf, P. Jean Henslee-Downey, 
Christopher Bredeson, Jean-Yves Cahn, et al. 1999. “Long-Term Survival and Late 
Deaths after Allogeneic Bone Marrow Transplantation.” New England Journal of 
Medicine 341 (1): 14–21. doi:10.1056/NEJM199907013410103. 
Sorror, Mohamed L., Michael B. Maris, Rainer Storb, Frederic Baron, Brenda M. Sandmaier, 
David G. Maloney, and Barry Storer. 2005. “Hematopoietic Cell Transplantation (HCT)-
Specific Comorbidity Index: A New Tool for Risk Assessment before Allogeneic HCT.” 
Blood 106 (8): 2912–19. doi:10.1182/blood-2005-05-2004. 
Steward, C. G., and A. Jarisch. 2005. “Haemopoietic Stem Cell Transplantation for Genetic 
Disorders.” Archives of Disease in Childhood 90 (12): 1259–63. 
doi:10.1136/adc.2005.074278. 
Storb, Rainer, Boglarka Gyurkocza, Barry E. Storer, Mohamed L. Sorror, Karl Blume, Dietger 
Niederwieser, Thomas R. Chauncey, et al. 2013. “Graft-versus-Host Disease and Graft-
versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation.” Journal of 
Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 
(12): 1530–38. doi:10.1200/JCO.2012.45.0247. 
Tannu, Nilesh S., and Scott E. Hemby. 2006. “Two-Dimensional Fluorescence Difference Gel 
Electrophoresis for Comparative Proteomics Profiling.” Nature Protocols 1 (4): 1732–42. 
doi:10.1038/nprot.2006.256. 
Terwey, T. H., T. M. Le Duc, P. G. Hemmati, P. le Coutre, M. Nagy, P. Martus, B. Dörken, and 
R. Arnold. 2013. “NIH-Defined Graft-versus-Host Disease and Evidence for a Potent 
Graft-versus-Leukemia Effect in Patients with Acute Lymphoblastic Leukemia.” Annals 
of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 24 
(5): 1363–70. doi:10.1093/annonc/mds615. 
Thomas, E. Donnall, Harry L. Lochte, Joe H. Cannon, Otto D. Sahler, and Joseph W. Ferrebee. 
1959. “SUPRALETHAL WHOLE BODY IRRADIATION AND ISOLOGOUS 
MARROW TRANSPLANTATION IN MAN*.” Journal of Clinical Investigation 38 (10 
Pt 1-2): 1709–16. 
Ukena, Sya N., Robert Geffers, Stefanie Buchholz, Michael Stadler, and Anke Franzke. 2012. 
“Biomarkers for Acute and Chronic Graft-versus-Host Disease in Regulatory T Cells.” 
Transplant Immunology 27 (4): 179–83. doi:10.1016/j.trim.2012.07.003. 
  
52 
 
Vigorito, Afonso C., Paulo V. Campregher, Barry E. Storer, Paul A. Carpenter, Carina K. 
Moravec, Hans-Peter Kiem, Matthew L. Fero, et al. 2009. “Evaluation of NIH Consensus 
Criteria for Classification of Late Acute and Chronic GVHD.” Blood 114 (3): 702–8. 
doi:10.1182/blood-2009-03-208983. 
Wang, Hong, Shawn G. Clouthier, Vladimir Galchev, David E. Misek, Ulrich Duffner, Chang-Ki 
Min, Rong Zhao, et al. 2005. “Intact-Protein-Based High-Resolution Three-Dimensional 
Quantitative Analysis System for Proteome Profiling of Biological Fluids.” Molecular & 
Cellular Proteomics: MCP 4 (5): 618–25. doi:10.1074/mcp.M400126-MCP200. 
Wingard, J. R., S. Piantadosi, G. B. Vogelsang, E. R. Farmer, D. A. Jabs, L. S. Levin, W. E. 
Beschorner, R. A. Cahill, D. F. Miller, and D. Harrison. 1989. “Predictors of Death from 
Chronic Graft-versus-Host Disease after Bone Marrow Transplantation.” Blood 74 (4): 
1428–35. 
Xie, Lin-Na, Fang Zhou, Xi-Min Liu, Yuan Fang, Zhe Yu, Ning-Xia Song, and Fan-Sheng Kong. 
2014. “Serum microRNA155 Is Increased in Patients with Acute Graft-versus-Host 
Disease.” Clinical Transplantation 28 (3): 314–23. doi:10.1111/ctr.12314. 
 
  
  
53 
 
CURRICULUM VITAE 
Joshua J. Geary 
114 Tolman Street 
Newton, MA 02465 
1982 
Work Experience  
  
Systems Business Analyst, Dana-Farber Cancer Institute, Cell Manipulation and Gene 
Transfer Core Facility (CMCF), Boston, MA.  
March 2013 – current 
 Create and revise standard operating procedures relevant to electronic systems.   
 Script, Execute, Review test plans and validation plans in compliance with all 
applicable regulations and standards (software and hardware) 
 Create detailed specifications for software purchase, stressing business needs and 
regulatory compliance 
 Perform Solution Assessment and Validation for vendor’s proposed software 
enhancements.   
 
Cell Processing Technologist, Dana-Farber Cancer Institute, Cell Manipulation and Gene 
Transfer Core Facility (CMCF), Boston, MA.  
September 2008 – March 2013 
● Process cellular products for clinical use and clinical trials according to current 
good manufacturing practice (cGMP), current good tissue practices and FACT 
standards. 
● Use flow cytometry to identify cell populations for clinical and research use. 
● Create and revise standard operating procedures, and qualify equipment and 
procedures for use. 
● Review processes and batch records for compliance with regulatory agencies and 
internal quality assurance. 
● Create and execute validations in compliance with all applicable regulations and 
standards.  
 
Medical Technician I, Massachusetts General Hospital, Boston, MA.  
June 2005 – September 2008 
● Worked in a high volume clinical chemistry laboratory, running various blood and 
urine tests, reporting values to clinicians, and processing samples.   
● Maintained standards of precision and accuracy to ensure timely reporting of 
patient results. 
  
Projects and publications: 
 
  
54 
 
Implementation of HPC screening test to determine the initiation of autologous apheresis 
● The HPC screening test is currently in use at DFCI 
● Data presented at AABB annual meeting, abstract published in supplement 
● Full length article with expanded data set and analysis in publication 
Validation and Implementation of the WBC-D test for determining the total nucleated cell 
count of HPC marrow products 
● Currently in use by CMCF, used to determine recoveries for HPC marrow product 
manipulations 
 
Memantine attenuates spatial and working memory impairment in Sprague Dawley rats 
induced by a zinc deficient diet  
Advisor: Dr. Anne Jane Tierney  
● Crafted a thesis, built a set of experiments and controls, ran the study, and analyzed 
and interpreted data in five months.  
 
Characterization of cyclin-dependent kinase 5 (cdk5)/p35-regulated kinase (cprk): kinase 
activity and putative substrates 
Advisors: Dr. Harish Pant, Dr. Sashi Kesavapany  
● Worked independently on a project search for substrates of a novel kinase, 
culminating in a report on the work and a presentation and poster session at 
Building 10 on the NIH campus.    
 
 Regulation of neurofillament phosphorylation in the squid giant axon 
Advisor: Dr. Phillip Grant  
● Dissected and prepared squid giant axons 
● Analyzed phosphorylation state of neurofilament proteins when exposed to various 
kinases using western blot and mass spectrometry    
  
Education  
  
Colgate University, Hamilton, New York  
Bachelor of Arts Degree, May 2004  
Concentration:  Neuroscience, Cellular   
Overall GPA: 3.34 
  
Boston University, Boston, Massachusetts  
Master of Arts Medical Sciences 
Current GPA 3.78 completion date: 2015 
 
Skills 
 
MS Office suite, Sunquest, EdgeCell, EPIC/Sunquest intergration, SAS (statistics) 
